Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GALECTIN THERAPEUTICS INC Director's Dealing 2015

Jul 8, 2015

33422_dirs_2015-07-08_1c0e5174-7032-4c9b-a16c-c8adbeb74b5f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2015-03-12

Reporting Person: FREEMAN KEVIN D (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2015-03-12 Common Stock A 11112 Acquired 17112 Direct
2015-04-08 Common Stock A 10531 Acquired 27643 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2015-04-08 Stock Option (right to buy) $8.10 D 14815 Disposed 2021-06-02 Common Stock (14815) Direct

Footnotes

F1: Amount reported includes shares acquired on June 1, 2015 and previously reported on a Form 4 filed on June 2, 2015. Shares acquired on June 1, 2015 were originally reported as held indirectly by the reporting person, however, such shares are held directly by the reporting person.

F2: The option vested quarterly in eight equal installments beginning September 2, 2011.

F3: The option was canceled by mutual agreement of the reporting person and Galectin Therapeutics, Inc. The reporting person received 10,531 shares of restricted common stock, reported in Table 1 of this Form 4, as consideration for the cancellation of options granted on June 2, 2011 and March 28, 2013.